The company's board of directors approved the acquisition of 100% equity in Shanghai Jinfu Ruiming Biotechnology Co., Ltd. for RMB 35.0668 million. This acquisition aligns with the company's "15th Five-Year Plan" strategy to expand into the upstream medical industry supply chain. The transaction is considered a related-party transaction, with certain directors abstaining from voting.
Summary generated by AI · Always verify with source document
Stock Code: 301584
Stock Abbreviation: Jinfu Zhixin
Announcement Number: 2026-039
Shanghai Jinfu Zhixin Medical Technology Group Co., Ltd.
Announcement on the Resolution of the 17th Meeting of the Third Board of Directors
The Company and all members of the Board of Directors guarantee the authenticity, accuracy, and completeness of the information disclosed, and are free from false records, misleading statements, or material omissions.
I. Convening of the Board Meeting
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.